Abstract

Introduction: Varicella zoster virus is an exclusively human neurotrophic virus. The primary infection with the virus causes varicella. The virus remains latent in nervous tissue and upon secondary activation causes a variety of syndromes involving the central nervous system (CNS) including meningoencephalitis and cerebellitis. Materials and Methods: In this study, we looked at the epidemiology, clinical and laboratory features, and outcomes of patients who were admitted with varicella zoster of the CNS from 2005 to 2014. Results: There were 17 patients. Fever was present in 13 patients, seizures in 9 patients and headache and vomiting in 4 patients each. A generalized varicella rash was present in 8 out of 17 patients. A single dermatomal herpes zoster was present in seven patients. Two patients had no rash. Varicella zoster polymerase chain reaction (PCR) in cerebrospinal fluid (CSF) was done in 5 patients of which 4 were positive and 1 was negative. Nine patients had diabetes with an average glycated hemoglobin of 8.6%. Total number of deaths was five. Conclusions: Patients with diabetes who develop varicella or herpes zoster may be at risk for CNS complications. The diagnosis of varicella encephalitis has to rest on a combination of clinical findings and CSF PCR, as neither the rash nor the PCR is sensitive enough to diagnose all the cases with varicella encephalitis.

Keywords: Varicella, varicella meningoencephalitis, varicella zoster virus

Introduction

Varicella zoster virus (VZV) is an exclusively human, neurotropic, alpha herpes virus causing infections worldwide. Primary infection with the virus causes varicella after which the virus remains dormant in the ganglia of the cranial nerves, dorsal roots, and the autonomic neurons for a long time. A decline in the cell-mediated immunity results in virus reactivation causing a spectrum of neurological syndromes such as herpes zoster, vasculopathy, myelopathy, retinal necrosis, cerebellitis, and zoster sine herpete. Primary varicella infection predominantly affects children <10 years of age. Adults account up to 7%. Varicella meningoencephalitis has an incidence of 1–2 episodes/10,000 varicella cases with the highest incidence among adults and infants. The main aim of this article is to describe the clinical, laboratory and radiological features, and factors influencing the outcome in patients with VZV central nervous system (CNS) infection.

Subjects and Methods

In this retrospective case series, we included patients discharged with a diagnosis of varicella zoster CNS infection (meningitis or encephalitis or both) during the period 2005–2014 in Christian Medical College in Vellore, South India which is a Tertiary Teaching Hospital with an average of 2500 inpatients and 8000 outpatients/day. The predominant catchment area for the hospital includes the districts of Vellore and Tiruvannamalai in Tamil Nadu state and Chittoor district of the Andhra Pradesh state. The study was approved by the Institutional Review Board and the Ethics Committee. The data were collected from the electronic database and the inpatient records.
Carey, et al.: Varicella zoster infection of the central nervous system

Annals of Indian Academy of Neurology ¦ Volume 20 ¦ Issue 2 ¦ April-June 2017

were discharged against medical advice. Four patients were
all the patients received intravenous acyclovir. Two patients

Treatment and outcome
All the patients received intravenous acyclovir. Two patients
were discharged against medical advice. Four patients were

RESULTS
Demography
There were a total of 17 patients. The average age of the
patients was 50 years (range 19–86 years). There were
11 males and 6 females. The average duration of illness was
5.5 days (range: 1–20 days).

Clinical features
Fever was present in 13 patients, seizures in 9 patients and
headache and vomiting in 4 patients each. A generalized
varicella rash was present in 8 out of 17 patients. Herpes
zoster rash restricted to one dermatome was present in seven
patients. Four of these involved the trigeminal nerve, one
involved the C5 dermatome, one involved the D4 dermatome
and one involved the D6 dermatome. Two patients had no
rash. The single patient with HIV infection had presented
with a dermatomal zoster rash generalized tonic–clonic
seizures and unresponsiveness for 48 h. He responded well
to acyclovir and had an uneventful recovery. He had no other
opportunistic infections. CD4 count was unavailable for this
patient. Nine patients had diabetes with average glycated
hemoglobin (HbA1C) of 8.6%. Leukocytosis (total white
blood cell [WBC] count >10,000 cells/mm³) was present in
ten patients (mean: 12,976 cells/mm³). Six patients had renal
failure (serum creatinine >1.4 mg/dl). The mean CSF WBC
count was 93 cells/mm³ (range 0–510 cells). All of them
had lymphocytic predominance. PCR for VZV was done in
5 patients of which 4 were positive and 1 was negative.

Imaging
Six patients had magnetic resonance imaging (MRI) of the
brain of which four had abnormal findings. The MRI brain
and spinal cord of a patient who had presented with ascending
weakness and seizure with a herpes zoster rash showed bilateral
cortical-subcortical swelling involving the insular cortex, left
medial temporal, cingulate, and inferior frontal gyri with areas
of restricted diffusion and vasogenic edema with a suspicious
focus of bleed in the left insular cortex. There was significant
thoracic cord swelling with areas of hemorrhage [Figure 1].
Another patient had cortical and subcortical patchy areas of
T2-weighted and FLAIR hyperintensities in the right frontal
and parietal lobes with hemorhagic transformation. There was
a loss of flow void on T2-weighted images in the right internal
carotid artery suggestive of thrombosis [Figure 2]. The other
two patients had nonspecific abnormal findings on the MRI.

Discussion
Varicella encephalitis is a dreaded complication of varicella
infection affecting people of all age groups. Of the seventeen
patients, only one was immunocompromised (6%). This
finding is comparable to results from other studies –18% in
Switzerland,[4] 12% in the United States,[5] and 10% in
Israel.[6] The single patient with immunocompromised state
had HIV infection.

A significant finding of our study is that 9 of the 17 patients
had diabetes mellitus [Table 1]. The majority of these patients
had uncontrolled diabetes with an average HbA1C of 8.6%.
Four of these nine patients either died or were discharged
against medical advice. This finding deserves special attention.
Okamoto et al. have shown that patients with diabetes have
significantly lower cell-mediated immunity to VZV than
those without diabetes.[7] While previous studies have shown

mechanically ventilated of which three of them expired.
Total number of deaths was five. The first patient was in the
postpartum period. She had a breast abscess complicated by
septic shock with multi-organ dysfunction which ultimately led
to her death. The second patient died of aspiration pneumonia.
The third patient had encephalitis with associated myelitis and
required mechanical ventilation. She died of worsening
encephalitis and respiratory failure. The fourth patient was
an 86-year-old man who developed health-care-associated
pneumonia. He was managed conservatively without invasive
ventilation and succumbed to his illness. The fifth patient
developed left-sided hemiparesis and had a thrombus in the
right internal carotid artery. She also had a catheter-related
bacteremia with septic shock and multiorgan dysfunction.
Table 1: Individual clinical and laboratory features of the 17 patients with varicella zoster virus infection of the central nervous system

| Number | Sex   | Age (years) | Duration of illness in days | Clinical features                                      | Rash                        | Risk factors | HbA1c (g %) | CSF WBC count (cells/mm³) | CSF VZV PCR | Treatment received | Mechanical ventilation | Outcome |
|--------|-------|-------------|-----------------------------|--------------------------------------------------------|----------------------------|--------------|-------------|---------------------------|-------------|------------------------|------------------------|---------|
| 1      | Male  | 65          | 2                           | Fever, headache, vomiting, seizures                    | None                       | Diabetes     | 8.2         | 510                       | Positive    | Acyclovir              | No                     | Improved |
| 2      | Male  | 48          | 5                           | Fever, altered mentation                               | Varicella                  | Diabetes     | 7.2         | Not done                  | Not done    | Acyclovir              | No                     | Improved |
| 3      | Female | 71        | 2                           | Fever, headache                                       | Zoster rash - trigeminal nerve | Diabetes     | 8.1         | 60                        | Not done    | Acyclovir              | No                     | DAMA*    |
| 4      | Male  | 27          | 4                           | Fever, seizures                                       | Varicella                  | -            | -           | 2                         | Not done    | Acyclovir              | No                     | Improved |
| 5      | Female | 65        | 1                           | Headache, vomiting                                    | Varicella                  | -            | -           | 50                        | Not done    | Acyclovir              | No                     | Improved |
| 6      | Male  | 22          | 3                           | Fever, altered mentation                               | Zoster rash - trigeminal nerve | Diabetes     | 7.0         | 170                       | Not done    | Acyclovir              | No                     | Improved |
| 7      | Female | 34        | 20                          | Fever, seizures                                       | Varicella                  | -            | -           | 3                         | Not done    | Acyclovir              | Yes                    | Died     |
| 8      | Male  | 76          | Not known                   | Fever, altered mentation                               | Varicella                  | -            | -           | 0                         | Not done    | Acyclovir              | No                     | Died     |
| 9      | Male  | 46          | 10                          | Vomiting, altered mentation                            | Zoster rash - C4 dermatome | -            | -           | 38                        | Not done    | Acyclovir              | No                     | Improved |
| 10     | Female | 68        | 2                           | Seizures, ascending weakness                           | Zoster rash - D6 dermatome | -            | -           | 95                        | Not done    | Acyclovir              | Yes                    | Died     |
| 11     | Male  | 86          | Not known                   | Fever, seizures                                       | None                       | Diabetes     | 5.9         | 290                       | Positive    | Acyclovir              | No                     | Improved |
| 12     | Male  | 19          | 7                           | Fever, altered mentation                               | Zoster rash - trigeminal nerve | -            | -           | 46                        | Positive    | Acyclovir              | No                     | Died     |
| 13     | Male  | 30          | 6                           | Fever, seizures                                       | Varicella                  | -            | -           | 50                        | Not done    | Acyclovir              | No                     | Improved |
| 14     | Female | 30       | 7                           | Fever, vomiting                                       | Varicella                  | 13.6         | 18          | Positive                  | Acyclovir   | Yes                    | Improved |
| 15     | Female | 43        | 7                           | Fever, headache                                       | Zoster rash - trigeminal nerve | Diabetes     | NA          | 85                        | Negative    | Acyclovir              | Yes                    | Died     |
| 16     | Male  | 55          | 4                           | Seizures                                               | Varicella                  | NA           | 55          | Not done                 | Acyclovir   | No                     | DAMA*                  | Died     |
| 17     | Male  | 55          | 3                           | Fever, seizures                                       | Zoster rash - C5 dermatome | HIV infection | -          | 10                        | Not done    | Acyclovir              | No                     | Improved |

*DAMA = Discharged against medical advice, NA = Not available, HbA1c = Glycated hemoglobin, WBC = White blood cell, CSF = Cerebrospinal fluid, VZV = Varicella-zoster virus, PCR = Polymerase chain reaction

that diabetes is a risk factor for herpes zoster,[8,9] the same has not been shown for varicella encephalitis. Our finding is particularly relevant for developing countries where varicella vaccination is not part of the national immunization programs, but the prevalence of diabetes is alarmingly on the rise. It is possible that in these countries the number of cases with varicella encephalitis may rise in the future. Vaccination may be the solution to this problem. Ampofo et al. followed up 461 healthy adults after varicella vaccination and showed that varicella vaccine was effective in protecting adults from serious VZV disease in the long-term.[10] Hata et al. have shown that varicella vaccine (Oka) is effective in inducing cell-mediated immunity is elderly subjects with or without diabetes.[11] Given these findings, patients with diabetes and varicella or herpes zoster should be treated aggressively. Varicella vaccination should also be considered for all diabetics who have not had varicella in the past.

Two patients had no clinical evidence of a vesicular rash, but the diagnosis was made based on PCR implying a possibility of varicella encephalitis even in the absence of a rash. Becerra et al. also reported that only 5 out of 11 patients (45%) had a vesicular rash in patients with varicella meningoencephalitis.[4] In another study, from California, only 11 out of 26 patients (42%) who tested positive for VZV PCR had a rash.[5] In a study from the UK, seven out of eight patients (88%) with CNS varicella infection had a rash. This suggests that varicella should be suspected in any patient with encephalitis and it may be prudent to check for VZV PCR in CSF even in the absence of a rash. The common practice of stopping acyclovir if HSV PCR is negative should be abandoned.[4]

One of our patients had a negative VZV PCR. This female patient aged 45 years presented with fever, headache, and seizures and had a vesicular rash involving the trigeminal
nerve. She required mechanical ventilation and in the course of the illness developed occlusion of the right internal carotid artery with hemiparesis. CSF PCR for VZV, though highly specific, has a sensitivity of only 60%. In such cases, anti-VZV IgM antibody may be useful in making a diagnosis.\cite{12}

Three patients did not have CSF pleocytosis. Becerra \textit{et al.} noted that in their series, only 50% of patients with encephalitis had CSF pleocytosis. Higher CSF pleocytosis is seen more in the meningitic spectrum of CNS VZV disease. VZV CNS infection in HIV infection also has a higher likelihood of presenting without CSF pleocytosis. Brown \textit{et al.} reported that only 6 out of 15 patients with VZV-associated neurological disease and HIV infection had CSF pleocytosis.\cite{13} The diagnosis in such patients has to be made clinically and based on VZV PCR.

**Conclusions**

VZV is one of the common etiological agents causing encephalitis, and the incidence seems to be increasing. In patients with concomitant diabetes mellitus and primary varicella infection or herpes zoster, there appears to be an increased risk for CNS disease. This has to be substantiated by a prospective study with a control arm. In the meantime, vaccination should be considered for diabetics without immunity to VZV, and those diabetics with varicella or herpes zoster should be aggressively treated with acyclovir. Diagnosis of varicella encephalitis has to rest on a combination of clinical findings and CSF PCR, as neither the rash nor the PCR is sensitive enough to diagnose all the cases with varicella encephalitis.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Mueller NH, Gilden DH, Cohrs RJ, Mahalingam R, Nagel MA. Varicella zoster virus infection: Clinical features, molecular pathogenesis of disease, and latency. Neurology 2008;26:675-97.

2. Available from: http://www.cdc.gov/vaccines/pubs/pinkbook/varicella.html#epi. [Last retrieved on 2016 Jun 22].

3. Gnann JW Jr. Varicella-zoster virus: A typical presentations and unusual complications. J Infect Dis 2002;186 Suppl 1:S91-8.

4. Becerra JC, Sieber R, Martinetti G, Costa ST, Meylan P, Bernasconi E. Infection of the central nervous system caused by varicella zoster virus reactivation: A retrospective case series study. Int J Infect Dis 2013;17:e529-34.

5. Pahud BA, Glaser CA, Dekker CL, Arvin AM, Schmid DS. Varicella zoster disease of the central nervous system: Epidemiological, clinical, and laboratory features 10 years after the introduction of the varicella vaccine. J Infect Dis 2011;203:316-23.

6. Pollak L, Dovrat S, Book M, Mendelson E, Weinberger M. Varicella zoster vs. herpes simplex meningoencephalitis in the PCR era. A single center study. J Neurol Sci 2012;314:29-36.

7. Okamoto S, Hata A, Sadaoka K, Yamanishi K, Mori Y. Comparison of varicella-zoster virus-specific immunity of patients with diabetes mellitus and healthy individuals. J Infect Dis 2009;200:1606-10.

8. Hata A, Kuniyoshi M, Ohkusa Y. Risk of Herpes zoster in patients with underlying diseases: A retrospective hospital-based cohort study. Infection 2011;39:537-44.

9. Heymann AD, Chodick G, Karpati T, Kamer L, Kremer E, Green MS, \textit{et al.} Diabetes as a risk factor for herpes zoster infection: Results of a population-based study in Israel. Infection 2008;36:226-30.

10. Ampofo K, Saiman L, LaRussa P, Steinberg S, Annunziato P, Gershon A. Persistence of immunity to live attenuated varicella vaccine in healthy adults. Clin Infect Dis 2002;34:774-9.

11. Hata A, Inoue F, Hamamoto Y, Yamasaki M, Fujikawa J, Kawahara H, \textit{et al.} Efficacy and safety of live varicella zoster vaccine in diabetes: A randomized, double-blind, placebo-controlled trial. Diabet Med 2016;33:1094-101.

12. Debiasi RL, Tyler KL. Molecular methods for diagnosis of viral encephalitis. Clin Microbiol Rev 2004;17:903-25.

13. Brown M, Scarborough M, Brink N, Manji H, Miller R. Varicella zoster virus-associated neurological disease in HIV-infected patients. Int J STD AIDS 2001;12:79-83.